Spero Therapeutics SPRO Stock
Spero Therapeutics Price Chart
Spero Therapeutics SPRO Financial and Trading Overview
| Spero Therapeutics stock price | 1.22 USD |
| Previous Close | 1.21 USD |
| Open | 1.22 USD |
| Bid | 0.89 USD x 200 |
| Ask | 1.85 USD x 100 |
| Day's Range | 1.21 - 1.25 USD |
| 52 Week Range | 1.08 - 3.08 USD |
| Volume | 353.86K USD |
| Avg. Volume | 1.61M USD |
| Market Cap | 71.05M USD |
| Beta (5Y Monthly) | 1.484 |
| PE Ratio (TTM) | 8.714286 |
| EPS (TTM) | 0.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4 USD |
SPRO Valuation Measures
| Enterprise Value | 22.32M USD |
| Trailing P/E | 8.714286 |
| Forward P/E | -1.0990992 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.5117239 |
| Price/Book (mrq) | 1.6052632 |
| Enterprise Value/Revenue | 0.475 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Spero Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.484 |
| 52-Week Change | -34.054% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 3.08 USD |
| 52 Week Low | 1.08 USD |
| 50-Day Moving Average | 1.71 USD |
| 200-Day Moving Average | 2.28 USD |
SPRO Share Statistics
| Avg. Volume (3 month) | 1.61M USD |
| Avg. Daily Volume (10-Days) | 570.14K USD |
| Shares Outstanding | 58.23M |
| Float | 46.72M |
| Short Ratio | 0.73 |
| % Held by Insiders | 22.61% |
| % Held by Institutions | 18.22% |
| Shares Short | 1.51M |
| Short % of Float | 3.14% |
| Short % of Shares Outstanding | 2.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 15.70% |
| Operating Margin (ttm) | 14.06% |
| Gross Margin | 56.31% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | 7.19% |
| Return on Equity (ttm) | 19.16% |
Income Statement
| Revenue (ttm) | 47M USD |
| Revenue Per Share (ttm) | 0.83 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 26.47M USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | 7.38M USD |
| Diluted EPS (ttm) | 0.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 50.77M USD |
| Total Cash Per Share (mrq) | 0.87 USD |
| Total Debt (mrq) | 2.04M USD |
| Total Debt/Equity (mrq) | 4.62 USD |
| Current Ratio (mrq) | 6.121 |
| Book Value Per Share (mrq) | 0.76 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 19.58M USD |
| Levered Free Cash Flow (ttm) | 28.85M USD |
Profile of Spero Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 675 Massachusetts Avenue |
| ZIP | 02139 |
| Phone | 857 242 1600 |
| Website | https://sperotherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 25 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Q&A For Spero Therapeutics Stock
What is a current SPRO stock price?
Spero Therapeutics SPRO stock price today per share is 1.22 USD.
How to purchase Spero Therapeutics stock?
You can buy SPRO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Spero Therapeutics?
The stock symbol or ticker of Spero Therapeutics is SPRO.
Which industry does the Spero Therapeutics company belong to?
The Spero Therapeutics industry is Biotechnology.
How many shares does Spero Therapeutics have in circulation?
The max supply of Spero Therapeutics shares is 58.23M.
What is Spero Therapeutics Price to Earnings Ratio (PE Ratio)?
Spero Therapeutics PE Ratio is 8.71428600 now.
What was Spero Therapeutics earnings per share over the trailing 12 months (TTM)?
Spero Therapeutics EPS is 0.14 USD over the trailing 12 months.
Which sector does the Spero Therapeutics company belong to?
The Spero Therapeutics sector is Healthcare.
Spero Therapeutics SPRO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12848.65 USD — |
+0.42
|
— — | 12783.89 USD — | 12893.08 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7285.19 USD — |
+1.34
|
— — | 7209.03 USD — | 7347.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32315.97 USD — |
+0.44
|
— — | 32154.08 USD — | 32426.3 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
